In conclusion, higher infusion of TIL and CD8+ TIL, lower infusion of CD8+PD1+ TIL and CD4+FoxP3+ TIL, and infection with HPV and occurrence of fever are potential factors for predicting the clinical response to combination therapy of TILs and anti-PD1. This evidence concerns the gene CD8A and infection.